107.55 -1.25 (-1.15%)
Before hours: 8:16AM EST
|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||108.56 - 111.30|
|52-week range||62.55 - 113.41|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||23.80|
|Earnings date||03 Feb 2021|
|Forward dividend & yield||5.20 (4.78%)|
|Ex-dividend date||14 Jan 2021|
|1y target est||117.48|
AbbVie (ABBV) closed at $108.80 in the latest trading session, marking a -1.54% move from the prior day.
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. CoolSculpting® Elite harnesses proven CoolSculpting® technology to target, freeze, and eliminate treated fat cells. CoolSculpting® Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.
As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new drugs, like its best-selling arthritis treatment Humira. There's two reasons AbbVie is worth holding forever: its skill with drug development, and its generous dividend. Like many other pharma companies, AbbVie maximizes the revenue that it gets from each of its drug development projects by investigating their usefulness for multiple illnesses.